## WST: West Pharmaceutical Services, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.8% below STRENGTH zone (4.0-10.0%); PEG 3.50 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($263.75)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 1)

**1. West Pharmaceutical Services named Medtech Company of the Year at Irish Medtech Awards**
- Source: Business Plus | 20251205T103737 | Bullish | Relevance: 100%
- West Pharmaceutical Services Inc. was awarded Medtech Company of the Year at the 2025 Irish Medtech Awards for its significant impact on patient care, employment growth in Dublin, and strategic business optimization. The awards recognized various companies and organizations across different categories for their leadership and innovation within Ireland's â‚¬13bn medtech sector. Other winners included Palliare, CergenX, Alcon Ireland, Johnson & Johnson Vision Care Ireland, and Stryker, with a special award for outstanding contribution given to Tom Kelly.

**2. West Pharmaceutical Services (WST) Rebounded in Q3**
- Source: Insider Monkey | 20251204T084500 | Bullish | Relevance: 100%
- West Pharmaceutical Services (NYSE: WST) showed a rebound in the third quarter of 2025, driven by strong earnings and the hiring of a new CFO, leading to a 20% stock increase. The company reported $805 million in revenues, a 5% organic increase. Despite this, Brown Advisory's Large-Cap Growth Strategy noted that while WST performed well, their conviction leans towards AI stocks with potentially higher and quicker returns.

**3. West Pharmaceutical Services (WST) Rebounded in Q3**
- Source: Finviz | 20251204T084500 | Bullish | Relevance: 100%
- West Pharmaceutical Services, Inc. (NYSE: WST) continued to rebound in Q3 2025, with its stock moving 20% higher after a strong earnings report. The company reported $805 million in revenues, a 5% organic increase. Despite this, Brown Advisory's Large-Cap Growth Strategy noted that they believe certain AI stocks offer greater upside potential with less downside risk.

**4. 3 Reasons WST is Risky and 1 Stock to Buy Instead**
- Source: Finviz | 20251203T230100 | Bearish | Relevance: 100%
- This article outlines three reasons to be cautious about investing in West Pharmaceutical Services (WST): lackluster revenue growth, a shrinking adjusted operating margin, and declining return on invested capital (ROIC). Despite recent stock performance, the company's business quality is deemed to fall short of analyst standards, leading to a recommendation to look for better opportunities elsewhere, particularly in favored semiconductor stocks and the author's list of high-quality momentum stocks.

**5. JPMorgan Chase & Co. Sells 435,132 Shares of West Pharmaceutical Services, Inc. $WST**
- Source: MarketBeat | 20251203T000851 | Somewhat-Bullish | Relevance: 100%
- JPMorgan Chase & Co. significantly reduced its stake in West Pharmaceutical Services, Inc. by selling 435,132 shares in Q2 2025, now holding 220,044 shares valued at $48.15 million. Despite JPMorgan's reduction, other institutional investors like Swiss National Bank and Artisan Partners increased their positions, bringing total institutional ownership to 93.9%. West Pharmaceutical Services outperformed Q3 EPS expectations, provided strong FY2025 guidance, and maintains a "Moderate Buy" consensus analyst rating with an average target price of $349.20.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $285 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 2 ($0.14M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.9% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Vanguard Group Inc: 13.5% (+4.2%)
- Blackrock Inc.: 9.0% (-2.3%)
- State Street Corpora: 4.5% (-1.9%)
- Bank Of New York Mel: 4.0% (-9.4%)
- Artisan Partners Lim: 3.9% (+22.2%)

### Key Risks

1. Valuation stretched: PEG 3.5x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +1.1% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.50 signals overvaluation risk, limited margin of safety. Forward P/E 36.0x stretched relative to 10% growth. Quality metrics strong (ROA 10%, margin 16%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.35). Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $19.7B |
| Beta | 1.17 |
| 52W Range | $187.43 - $348.90 |
| Short Interest | 3.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.50 |
| Forward P/E | 36.0 |
| Current P/E | 39.4 |
| YoY Growth | 9.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -0.3% to 0.8% (+1.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.2pp (needs >4.0% for momentum thesis). MRS_5 (-0.0%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 3.1% shows strong absolute momentum above own 20MA. Outperforming sector by 3.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.30), confirming momentum. RSI neutral at 56. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.77% (CS: 61) | Neutral |
| RSI_14 | 55.5 | Neutral |
| MACD Histogram | 1.30 | Bullish |
| vs SMA20 | 1.031x | Above |
| vs SMA50 | 1.025x | Above |
| vs SMA200 | 1.172x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $280.23
- **Stop Loss:** $263.75 (5.9% risk)
- **Target:** $296.71 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 30
- **Position Value:** $8,406.90
- **Portfolio %:** 8.41%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-12 (Est: $1.83)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.71 | $1.96 | +14.5% |
| 2025Q2 | $1.54 | $1.84 | +19.7% |
| 2025Q1 | $1.26 | $1.45 | +15.3% |
| 2024Q4 | $1.73 | $1.82 | +5.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*